Amid global market ups and downs, TipRanks provides useful tools to help investors make decisions. One of its most powerful tools is the Smart Score, which rates stocks from 1 to 10 and shows their potential to outperform the market. Using this tool, we’ve identified three standout stocks: BioCryst (BCRX), Arista Networks (ANET), and Pharvaris (PHVS). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TipRanks’ Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
BioCryst (BCRX)
BioCryst Pharmaceuticals is a biotechnology company focused on developing oral drugs for rare diseases, especially treatments targeting complement-mediated and hereditary conditions. Year-to-date, BCRX stock has gained 20%.
Looking ahead, Wall Street analysts remain bullish, with seven covering analysts giving it a Buy rating. Meanwhile, BioCryst’s average stock price target of $21.14 suggests a potential upside of 125.4% from current levels.
Arista Networks (ANET)
Arista is a networking technology company that provides high-performance cloud networking solutions for data centers and large-scale AI and enterprise infrastructure. Year-to-date, ANET stock has gained 13%.
Wall Street analysts remain bullish on its upside potential, with 18 out of 18 analysts covering ANET stock, rating it as a Buy. According to TipRanks, the stock has a price target of $178.73, implying a 21% upside from current levels.
Pharvaris (PHVS)
Pharvaris is a clinical-stage biotech firm developing oral therapies for hereditary angioedema (HAE), a rare genetic condition causing severe swelling attacks. So far in 2026, PHVS stock has gained 0.13%.
PHVS stock carries a Strong Buy rating, with eight Buys and one Hold assigned in the past three months. The average price target of Pharvaris is $44.44, which implies a potential upside of 60%.
